Ultrafiltration FailureLUFFNCT05721703
An Observational Study of Long-term Peritoneal Dialysis Patients Who Eventually Develop Ultrafiltration Failure (LUFF)
An observational study of Ultrafiltration Failure, run by Chinese PLA General Hospital at 1 site in China.
Trial summary
At present, there are few researches on peritoneal dialysis, especially on ultrafiltration failure of peritoneal dialysis. To explore the regularity and mechanism of peritoneal ultrafiltration failure,investigators followed up the comprehensive data of participants from the insertion to the removal of the peritoneal… Read more about this study
- Who is it for?
- Ages 18 to 70 years
- Conditions the study is for
- Ultrafiltration Failure
- How many people
- 150 participants
- Where
- 1 siteChina
- Study dates
- 21 May 2021to 31 Dec 2029
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The patients who were diagnosed CKD5 age 18 to 70 need or keep peritoneal dialysis to treat or someone was ultrafiltration failure without AKI, pregnant or lactating women, active infection, infectious diseases and be asked to sign an "informed consent form".
Who may be able to join
- Clinically diagnosed as chronic renal insufficiency (CKD 5)
- Patients who met the first dialysis guidelines for peritoneal dialysis without catheter, or patients with peritoneal dialysis regularly, or ultrafiltration failure was diagnosed and patients on peritoneal dialysis were to be existed.
- Written informed consent signed by the patient or the authorized client has been obtained.
Who cannot join
- Acute renal failure.
- Pregnant or lactating women.
- Active infection duration.
- One of infectious serum markers of HIV, syphilis, hepatitis B and hepatitis C is positive.
- Any other conditions that the investigator considers impossible to join this trial.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Observe the Multi-indices of Long-term Peritoneal Dialysis Patients to Explore the Evolution of Peritoneal Ultrafiltration Failure
At present, there are few researches on peritoneal dialysis, especially on ultrafiltration failure of peritoneal dialysis. To explore the regularity and mechanism of peritoneal ultrafiltration failure,investigators followed up the comprehensive data of participants from the insertion to the removal of the peritoneal dialysis catheter, and collected the peritoneal tissue for morphological and single-cell analysis when the participants inserting or removing their catheters. If the catheter is still in use when this study stop collecting data, the peritoneal dialysis effluent will substitute for peritoneal tissue to the morphological and single-cell analysis. Clinical data and single-cell sequence data were processed using statistical analyses to identify factors affecting ultrafiltration failure.
Read the detailed description
Background: Chronic kidney disease (CKD) is one of the most common non-communicable diseases. The Global Burden of Disease (GBD), which examined multiple diseases in 188 countries from 1990 to 2013, found that the number of CKD patients increased from 318,665,000 to 47,1916,000, representing a 48% increase in prevalence (2.1% annually). Peritoneal dialysis is an important renal replacement therapy for participants with end-stage renal disease. The removal of water mainly depends on the high osmotic pressure of dialysate which is called ultrafiltration, and the loss of ultrafiltration function of peritoneum is called ultrafiltration failure. Data from the National Blood Purification Case Information System (CNRDS) show that the rate of conversion from ultrafiltration failure to hemodialysis is 5%-10%, and cardiovascular complications caused by fluid overload, such as malignant hypertension and heart failure, are the common causes of death. At the end of 2021, dialysis data in mainland China showed that there were nearly 880,000 patients undergoing dialysis treatment, of which 14% chose peritoneal dialysis, the average dialysis age of peritoneal dialysis patients was 50.3 months, the proportion of patients who had been on dialysis for more than 5 years was 33.9%, and the proportion of patients who had been on dialysis for more than 10 years was 7.5%. It can be seen that long-term peritoneal dialysis still has a high shedding rate, and ultrafiltration failure is the key problem of long-term peritoneal dialysis.
Methods: Investigators gathered participants from Department of Nephrology, PLA General Hospital, from May 2021 to May 2029. Inclusion Criteria: 1.Clinically diagnosed as chronic renal insufficiency (CKD 5); 2.Incident PD patients who were newly inserted PD catheter during the observation period of this study; 3.Prevalent PD patients who inserted PD cather before initiation of this study, should be admitted as pre-UFF, has taken long-term PD(>5 years) before removing cather during the observation period of this study; 4.Written informed consent signed by the patient or the authorized client has been obtained. Exclusion Criteria: 1.Acute renal failure; 2.Pregnant or lactating women; 3.Active infection duration; 4.One of infectious serum markers of HIV, syphilis, hepatitis B and hepatitis C is positive; 5.Any other conditions that the investigator considers impossible to join this trial. The observed indices were: (1)Demographic characteristics; (2)Peritoneal equilibration test (PET D/P), adequacy assessment(Ccr, Kt/V), evaluation of ultrafiltration (urine volume, intake,etc.); (3)Peritoneal dialysate routine examination, peritoneal dialysate inflammation examination and other markers and exosome examination; (4)Classification and counting of exfoliated cells from peritoneal dialysis effluent, and dialysate exfoliated cells primary culture for further cell biology analysis; (5)Peritoneal histopathology and immunohistochemical analysis and proteomics and single cell transcriptome analysis; (6)Clinical examinations: Routine blood test, Uroscopy, Blood biochemistry test, Coagulation function test, Immunoassay, Bone metabolism test, Thyroid function test, Evaluation of Ascites, etc. For an incident PD patient,after admission,the peritoneal catheter was inserted, and the data of the initial peritoneal equilibration test and clinical examinations were collected, and the peritoneal membrane was sampled for single-cell analysis. After that, the patient was followed up, and the data of the subsequent peritoneal equilibration test and clinical examinations were collected until the end point(technique failure) or the study end(8 years). The investigators collected the peritoneal tissue for single-cell sequencing when participants remove the catheters(for the technique failure patients). If the catheter is still in use when this study stop collecting data(8 years), the peritoneal dialysis effluent will substitute for peritoneal tissue to the morphological and single-cell analysis. For a prevalent patient who admitted as pre-UFF, investigators collected the final peritoneal equilibration test and clinical examination data then sample the peritoneal tissue for single-cell sequencing when removing the cather. SPSS and R were used for statistical analysis. Continuous variables were expressed as mean ± standard deviation, and discontinuous variables were expressed as percentage. The independent t-test or chi-square test was used for comparison between the two data. P<0.05 was statistically significant.
- Conditions
- Ultrafiltration Failure
- Keywords
- peritoneal dialysis, Ultrafiltration Failure, long-term
What is being measured
The primary outcome is the main question the study is designed to answer.
Technical survival rate
Technical survival of peritoneal dialysis
Measured: 8 year
Secondary outcomes (10)
D/P
Ratio of substance content in peritoneal dialysate to that in blood.
Measured: 1,2,3,4,5,6,7,8 year
OCG
Glucose transport rates measured by a double mini peritoneal equilibration test.
Measured: 1,2,3,4,5,6,7,8 year
Ccr
Creatinine clearance rate. Ccr=urinary creatinine concentration * urine volume per minute/blood creatinine concentration.
Measured: 1,2,3,4,5,6,7,8 year
Kt/V
Ratio of urea clearance to volume during unit dialysis time.
Measured: 1,2,3,4,5,6,7,8 year
Cell counting
Count the number of cells.
Measured: 1,2,3,4,5,6,7,8 year
Electrolyte
Content of ions.
Measured: 1,2,3,4,5,6,7,8 year
Blood biochemical index
Venous blood was obtained for biochemical examination.
Measured: 1,2,3,4,5,6,7,8 year
Urine protein
Urine test for protein content.
Measured: 1,2,3,4,5,6,7,8 year
Histopathology
With the consent of the patients, peritoneal tissue was taken to observe histological changes.
Measured: 1,2,3,4,5,6,7,8 year
Single-cell transcriptome sequencing
With the consent of the patients, tissues were taken for analysis. Isolate cells in the tissues and measure gene expression profiles.
Measured: 1,2,3,4,5,6,7,8 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Feb 2023
- Study start21 May 2021
- Primary completion31 Dec 2029 (estimated)
- Study completion31 Dec 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Ultrafiltration FailureStudies of the same condition, open and under way.
- More trials run by Chinese PLA General HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 150 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Chinese PLA General Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Jianhui Zhou, Chinese PLA General Hospital
- Investigators
- CHEN Xiangmei, yes, Study director, Chinese PLA General Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05721703
- Sponsor's protocol ID
- S2021-263-01
- Acronym
- LUFF
- Status last verified
- Feb 2023
- First submitted
- 4 Oct 2022
- Last updated
- 14 Feb 2023
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Feb 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Observe the Multi-indices of Long-term Peritoneal Dialysis Patients to Explore the Evolution of Peritoneal Ultrafiltration Failure
- ClinicalTrials.gov ID
- NCT05721703
- Acronym / sponsor ID
- LUFF / S2021-263-01
- Conditions
- Ultrafiltration Failure
- Keywords
- peritoneal dialysis, Ultrafiltration Failure, long-term
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 150 participants (estimated)
- Lead sponsor
- Chinese PLA General HospitalUniversity, hospital or other
- Study start
- 21 May 2021 (actual)
- Primary completion
- 31 Dec 2029 (estimated)
- Study completion
- 31 Dec 2029 (estimated)
- First posted
- 10 Feb 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
At present, there are few researches on peritoneal dialysis, especially on ultrafiltration failure of peritoneal dialysis. To explore the regularity and mechanism of peritoneal ultrafiltration failure,investigators followed up the comprehensive data of participants from the insertion to the removal of the peritoneal dialysis catheter, and collected the peritoneal tissue for morphological and single-cell analysis when the participants inserting or removing their catheters. If the catheter is still in use when this study stop collecting data, the peritoneal dialysis effluent will substitute for peritoneal tissue to the morphological and single-cell analysis. Clinical data and single-cell sequence data were processed using statistical analyses to identify factors affecting ultrafiltration failure.
Detailed description
Background: Chronic kidney disease (CKD) is one of the most common non-communicable diseases. The Global Burden of Disease (GBD), which examined multiple diseases in 188 countries from 1990 to 2013, found that the number of CKD patients increased from 318,665,000 to 47,1916,000, representing a 48% increase in prevalence (2.1% annually). Peritoneal dialysis is an important renal replacement therapy for participants with end-stage renal disease. The removal of water mainly depends on the high osmotic pressure of dialysate which is called ultrafiltration, and the loss of ultrafiltration function of peritoneum is called ultrafiltration failure. Data from the National Blood Purification Case Information System (CNRDS) show that the rate of conversion from ultrafiltration failure to hemodialysis is 5%-10%, and cardiovascular complications caused by fluid overload, such as malignant hypertension and heart failure, are the common causes of death. At the end of 2021, dialysis data in mainland China showed that there were nearly 880,000 patients undergoing dialysis treatment, of which 14% chose peritoneal dialysis, the average dialysis age of peritoneal dialysis patients was 50.3 months, the proportion of patients who had been on dialysis for more than 5 years was 33.9%, and the proportion of patients who had been on dialysis for more than 10 years was 7.5%. It can be seen that long-term peritoneal dialysis still has a high shedding rate, and ultrafiltration failure is the key problem of long-term peritoneal dialysis.
Methods: Investigators gathered participants from Department of Nephrology, PLA General Hospital, from May 2021 to May 2029. Inclusion Criteria: 1.Clinically diagnosed as chronic renal insufficiency (CKD 5); 2.Incident PD patients who were newly inserted PD catheter during the observation period of this study; 3.Prevalent PD patients who inserted PD cather before initiation of this study, should be admitted as pre-UFF, has taken long-term PD(>5 years) before removing cather during the observation period of this study; 4.Written informed consent signed by the patient or the authorized client has been obtained. Exclusion Criteria: 1.Acute renal failure; 2.Pregnant or lactating women; 3.Active infection duration; 4.One of infectious serum markers of HIV, syphilis, hepatitis B and hepatitis C is positive; 5.Any other conditions that the investigator considers impossible to join this trial. The observed indices were: (1)Demographic characteristics; (2)Peritoneal equilibration test (PET D/P), adequacy assessment(Ccr, Kt/V), evaluation of ultrafiltration (urine volume, intake,etc.); (3)Peritoneal dialysate routine examination, peritoneal dialysate inflammation examination and other markers and exosome examination; (4)Classification and counting of exfoliated cells from peritoneal dialysis effluent, and dialysate exfoliated cells primary culture for further cell biology analysis; (5)Peritoneal histopathology and immunohistochemical analysis and proteomics and single cell transcriptome analysis; (6)Clinical examinations: Routine blood test, Uroscopy, Blood biochemistry test, Coagulation function test, Immunoassay, Bone metabolism test, Thyroid function test, Evaluation of Ascites, etc. For an incident PD patient,after admission,the peritoneal catheter was inserted, and the data of the initial peritoneal equilibration test and clinical examinations were collected, and the peritoneal membrane was sampled for single-cell analysis. After that, the patient was followed up, and the data of the subsequent peritoneal equilibration test and clinical examinations were collected until the end point(technique failure) or the study end(8 years). The investigators collected the peritoneal tissue for single-cell sequencing when participants remove the catheters(for the technique failure patients). If the catheter is still in use when this study stop collecting data(8 years), the peritoneal dialysis effluent will substitute for peritoneal tissue to the morphological and single-cell analysis. For a prevalent patient who admitted as pre-UFF, investigators collected the final peritoneal equilibration test and clinical examination data then sample the peritoneal tissue for single-cell sequencing when removing the cather. SPSS and R were used for statistical analysis. Continuous variables were expressed as mean ± standard deviation, and discontinuous variables were expressed as percentage. The independent t-test or chi-square test was used for comparison between the two data. P<0.05 was statistically significant.
Study design
- Observational model
- Cohort
- Time perspective
- Other
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The patients who were diagnosed CKD5 age 18 to 70 need or keep peritoneal dialysis to treat or someone was ultrafiltration failure without AKI, pregnant or lactating women, active infection, infectious diseases and be asked to sign an "informed consent form".
Key inclusion criteria (3 listed)
- Clinically diagnosed as chronic renal insufficiency (CKD 5)
- Patients who met the first dialysis guidelines for peritoneal dialysis without catheter, or patients with peritoneal dialysis regularly, or ultrafiltration failure was diagnosed and patients on peritoneal dialysis were to be existed.
- Written informed consent signed by the patient or the authorized client has been obtained.
Key exclusion criteria (5 listed)
- Acute renal failure.
- Pregnant or lactating women.
- Active infection duration.
- One of infectious serum markers of HIV, syphilis, hepatitis B and hepatitis C is positive.
- Any other conditions that the investigator considers impossible to join this trial.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Technical survival rate
Time frame: 8 year
Technical survival of peritoneal dialysis
10 secondary outcomes
D/P
Time frame: 1,2,3,4,5,6,7,8 year
OCG
Time frame: 1,2,3,4,5,6,7,8 year
Ccr
Time frame: 1,2,3,4,5,6,7,8 year
Kt/V
Time frame: 1,2,3,4,5,6,7,8 year
Cell counting
Time frame: 1,2,3,4,5,6,7,8 year
Electrolyte
Time frame: 1,2,3,4,5,6,7,8 year
Blood biochemical index
Time frame: 1,2,3,4,5,6,7,8 year
Urine protein
Time frame: 1,2,3,4,5,6,7,8 year
Histopathology
Time frame: 1,2,3,4,5,6,7,8 year
Single-cell transcriptome sequencing
Time frame: 1,2,3,4,5,6,7,8 year
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Feb 2023.
Related trials for Ultrafiltration Failure
Recruiting
Early Deresuscitation Strategy Driven by Tissue Perfusion in Renal Replacement Therapy in Patients With Acute Renal Failure
Acute Kidney Injury, Fluid Overload
Recruiting
Dry Weight Reduction Intervention Via Extra Ultrafiltration
Fluid Accumulation, Blood Pressure Management
Recruiting
Hemodynamics in Chronic Hemodialysis Patients Undergoing Isolated Ultrafiltration Compared to Conventional Hemodialysis
End Stage Kidney Disease
Recruiting
The Microcirculation, Dialysis Modality and Sequestered Salt
End-stage Renal Disease
Active, not recruitingPhase 4
Effect of the Use of Dapagliflozin in Patients With Refractory Heart Failure
Heart Failure
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
CHEN Xiangmei, yes study director
Chinese PLA General Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Ultrafiltration Failure, run by Chinese PLA General Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 14 Feb 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Technical survival rate (time frame: 8 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Feb 2023.